Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
|
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
来源
PROSTATE | 2020年 / 80卷 / 01期
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
  • [1] Systematic evaluation of narrow-sense validity of polygenic risk score for prostate cancer in a Chinese prostate biopsy cohort
    Wu, Yishuo
    Ruan, Xiaohao
    Gao, Peng
    Da, Huang
    Fang, Zujun
    Xu, Danfeng
    Jiang, Haowen
    Ding, Qiang
    Lin, Xiaoling
    Lu, Daru
    Na, Rong
    CLINICAL GENETICS, 2023, 103 (06) : 636 - 643
  • [2] Concept and benchmarks for assessing narrow-sense validity of genetic risk score values
    Yu, Hongjie
    Shi, Zhuqing
    Wu, Yishuo
    Wang, Chi-Hsiung
    Lin, Xiaoling
    Perschon, Chelsea
    Isaacs, William B.
    Helfand, Brian T.
    Zheng, S. Lilly
    Duggan, David
    Mo, Zengnan
    Lu, Daru
    Xu, Jianfeng
    PROSTATE, 2019, 79 (10): : 1099 - 1105
  • [3] Polygenic risk score in prostate cancer
    Oh, Jong Jin
    Hong, Sung Kyu
    CURRENT OPINION IN UROLOGY, 2022, 32 (05) : 466 - 471
  • [4] Incorporation of Polygenic Risk Score into Guidelines for Inherited Risk Assessment for Prostate Cancer
    Xu, Jianfeng
    Isaacs, William B.
    EUROPEAN UROLOGY, 2021, 80 (02) : 139 - 141
  • [5] A Polygenic Risk Score for Prostate Cancer Risk Prediction
    Schaffer, Kerry R.
    Shi, Mingjian
    Shelley, John P.
    Tosoian, Jeffrey J.
    Kachuri, Linda
    Witte, John S.
    Mosley, Jonathan D.
    JAMA INTERNAL MEDICINE, 2023, 183 (04) : 386 - 388
  • [6] Performance of a polygenic risk score combined with clinical assessment for breast cancer risk
    Black, Mary Helen
    Li, Shuwei
    LaDuca, Holly
    Armasu, Sebastian
    Polley, Eric C.
    Fitz-Gibbon, Patrick
    Scott, Chris G.
    Winham, Stacey J.
    Olson, Janet E.
    Ruddy, Kathryn J.
    Vachon, Celine M.
    Couch, Fergus J.
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Validation of a prostate cancer polygenic risk score
    Black, Mary H.
    Li, Shuwei
    LaDuca, Holly
    Lo, Min-Tzu
    Chen, Jefferey
    Hoiness, Robert
    Gutierrez, Stephanie
    Tippin-Davis, Brigette
    Lu, Hsiao-Mei
    Gielzak, Marta
    Wiley, Kathleen
    Shi, Zhuqing
    Wei, Jun
    Zheng, Siqun Lilly
    Helfand, Brian T.
    Isaacs, William
    Xu, Jianfeng
    PROSTATE, 2020, 80 (15): : 1314 - 1321
  • [8] Prostate cancer risk prediction using a polygenic risk score
    Csilla Sipeky
    Kirsi M. Talala
    Teuvo L. J. Tammela
    Kimmo Taari
    Anssi Auvinen
    Johanna Schleutker
    Scientific Reports, 10
  • [9] Prostate cancer risk prediction using a polygenic risk score
    Sipeky, Csilla
    Talala, Kirsi M.
    Tammela, Teuvo L. J.
    Taari, Kimmo
    Auvinen, Anssi
    Schleutker, Johanna
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Prostate cancer polygenic risk score and prediction of lethal prostate cancer
    Robert J. Klein
    Emily Vertosick
    Dan Sjoberg
    David Ulmert
    Ann-Charlotte Rönn
    Christel Häggström
    Elin Thysell
    Göran Hallmans
    Anders Dahlin
    Pär Stattin
    Olle Melander
    Andrew Vickers
    Hans Lilja
    npj Precision Oncology, 6